BRIEF-Novartis Says Phase 3 Iridium Data In Lancet Respiratory Medicine Show Benefit Of Enerzair Breezhaler [Reuters]
Novartis AG (NVS)
Last novartis ag earnings: 4/28 01:00 am
Check Earnings Report
US:NYSE Investor Relations:
novartis.com/investors
Company Research
Source: Reuters
BRIEF-Novartis Says Phase 3 Iridium Data In Lancet Respiratory Medicine Show Benefit Of Enerzair Breezhaler July 10 (Reuters) - Novartis AG: * NOVARTIS PHASE III IRIDIUM DATA IN LANCET RESPIRATORY MEDICINE SHOW BENEFIT OF ENERZAIR® BREEZHALER® (QVM149), THE FIRST-IN-CLASS INHALED LABA/LAMA/ICS COMBINATION IN UNCONTROLLED ASTHMA * ONCE-DAILY ENERZAIR® BREEZHALER® (QVM149; IND/GLY/MF) WAS SUPERIOR TO ONCE-DAILY IND/MF (QMF149) IN IMPROVING THE LUNG FUNCTION OF PATIENTS WHOSE ASTHMA IS UNCONTROLLED WITH LABA/ICS STANDARD-OF-CARE TREATMENT * IN SECONDARY ANALYSES, IMPROVEMENTS IN LUNG FUNCTION WERE OBSERVED WITH HIGH- AND MEDIUM-DOSE IND/GLY/MF COMPARED TO HIGH-DOSE SAL/FLU * IN OTHER SECONDARY ANALYSES, CLINICALLY MEANINGFUL REDUCTIONS IN MODERATE-TO-SEVERE (36%) AND SEVERE (42%) ASTHMA EXACERBATION RATES WERE OBSERVED WITH HIGH-DOSE IND/GLY/MF COMPARED TO HIGH-DOSE SAL/FLU * IND/GLY/MF IS APPROVED IN EU, JAPAN AND CANADA, AND IS CURRENTLY UNDER REGULATORY REVIEW IN OTHER COUNTRIES Furth
Show less
Read more
Impact Snapshot
Event Time:
NVS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVS alerts
High impacting Novartis AG news events
Weekly update
A roundup of the hottest topics
NVS
News
- 20 Countries with the Highest Rates of Stomach Cancer in the World [Yahoo! Finance]Yahoo! Finance
- Novartis AG (NYSE: NVS) had its price target raised by analysts at BMO Capital Markets from $114.00 to $116.00. They now have a "market perform" rating on the stock.MarketBeat
- Roche Sales Decline in Last Quarter of Pandemic Impact [BNN Bloomberg (Canada)]BNN Bloomberg
- Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies <5 kg with malaria [Yahoo! Finance]Yahoo! Finance
- Why Novartis Stock Topped the Market on Tuesday [Yahoo! Finance]Yahoo! Finance
NVS
Earnings
- 4/23/24 - Beat
NVS
Sec Filings
- 4/23/24 - Form 6-K
- 2/15/24 - Form S-8
- 2/2/24 - Form SC
- NVS's page on the SEC website